Clinical TrialJun 2, 2026, 08:33 AM
Kura Oncology's Ziftomenib Combo Shows 87% ORR in AML Trial
AI Summary
Kura Oncology and Kyowa Kirin announced the publication of updated positive Phase 1a/b KOMET-007 trial results for ziftomenib in combination with venetoclax and azacitidine for relapsed/refractory NPM1-mutated AML. The data showed robust clinical activity, including high objective response rates and composite complete remission rates, particularly in venetoclax-naïve patients, with deep molecular responses and durable remissions. The investigational three-drug combination was well tolerated, supporting its continued evaluation in ongoing studies, including pivotal Phase 3 trials.
Key Highlights
- Ziftomenib combination showed 87% ORR and 70% CRc in venetoclax-naïve patients.
- 75% of venetoclax-naïve CRc responders achieved central MRD negativity.
- Median CRc duration was 9.2 months in venetoclax-naïve patients.
- Median OS not reached after 10.7 months follow-up in venetoclax-naïve patients.
- Venetoclax-experienced patients had 48% ORR and 24% CRc.
- The combination was well tolerated with low rates of differentiation syndrome (3%) and QTc prolongation.
Price Impact
More from KURA